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ABSTRACT: Introduction: Transforming growth factor-beta
(TGF-b) is a well-known regulator of fibrosis and inflammation
in many tissues. During embryonic development, TGF-b signal-
ing induces expression of the transcription factor scleraxis,
which promotes fibroblast proliferation and collagen synthesis in
tendons. In skeletal muscle, TGF-b has been shown to induce
atrophy and fibrosis, but the effect of TGF-b on muscle contrac-
tility and the expression of scleraxis and atrogin-1, an important
regulator of muscle atrophy, were not known. Methods: We
treated muscles from mice with TGF-b and measured force pro-
duction, scleraxis, procollagen Ia2, and atrogin-1 protein levels.
Results: TGF-b decreased muscle fiber size and dramatically
reduced maximum isometric force production. TGF-b also
induced scleraxis expression in muscle fibroblasts, and
increased procollagen Ia2 and atrogin-1 levels in muscles.
Conclusion: These results provide new insight into the effect of
TGF-b on muscle contractility and the molecular mechanisms
behind TGF-b–mediated muscle atrophy and fibrosis.
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Transforming growth factor-b1 (TGF-b) is a
secreted cytokine that plays important roles in the
biological activity of ﬁbroblasts and in the regula-
tion of extracellular matrix (ECM) production in
many tissues. TGF-b was originally identiﬁed as a
factor that promoted the proliferation of ﬁbroblast
cells and could transform normal cells into meta-
static cancer cells.1 Subsequent studies have shown
that TGF-b causes ﬁbrosis and promotes inﬂamma-
tion in multiple tissues including skin, liver, kid-
ney, lung, colon, heart, and skeletal muscle.2–7
Increased TGF-b signaling is also associated with
several diseases of skeletal muscle, including many
of the muscular dystrophies.8,9
TGF-b is a 25-kDa protein composed of two di-
sulﬁde-linked subunits that is secreted into the
ECM around cells in an inactive form bound to a
latency-associated peptide (LAP).3,9,10 The LAP is
degraded by proteases in the ECM, including ma-
trix metalloproteinase-2 (MMP-2), matrix metallo-
proteinase-9 (MMP-9), thrombospondin-1 (TSP-1),
bone morphogenetic protein 1/Tolloid-like (BMP-
1/TLD) metalloproteinases, as well as others.3,11
Many of these proteases become activated after
skeletal muscle injury or remain persistently acti-
vated in several different types of skeletal muscle
diseases.12 Once TGF-b is released from the LAP
and becomes activated, it associates with TGF-b
type II (TGFbRII) and type I (TGFbRI) serine/
threonine kinase transmembrane receptors.7,10
The activated TGFbRI receptor activates two signal-
ing pathways, the Smad2/3 pathway and the TAK1
MAPK pathway, which mediate many of the intra-
cellular actions of TGF-b, including synthesis of
ECM proteins, cell motility, and others.7,10
In addition to causing severe ﬁbrosis in many
different tissues, the systemic administration of
TGF-b leads to profound cachexia and muscle atro-
phy.6 The ubiquitin–proteasome system is impor-
tant in the regulation of the protein turnover rates
and size of muscle ﬁbers.13 Atrogin-1 (MAFbx) is
an E3 ubiquitin ligase expressed in skeletal muscle
that directs the polyubiquitination of proteins to
target them for proteolysis by the 26S protea-
some.14,15 Atrogin-1 levels increase after immobili-
zation or denervation, and mice that are deﬁcient
in atrogin-1 are resistant to denervation-induced
skeletal muscle atrophy.14 Insulin-like growth fac-
tor-1 (IGF-1) promotes muscle hypertrophy in part
by downregulating atrogin-1 expression via the
PI3K–Akt–Foxo3 pathway.16 Treatment of myo-
tubes with a cytokine that is related to TGF-b, myo-
statin, was found to induce the atrophy of myo-
tubes and increased atrogin-1 expression and
protein ubiquitination.17 The molecular mecha-
nisms behind muscle atrophy mediated by TGF-b,
however, are not well understood.
Scleraxis (Scx) is a bHLH transcription factor
that is expressed in ﬁbroblasts in the connective tis-
sue of limbs during development.18 Scleraxis pro-
motes ﬁbroblast proliferation and type I collagen
synthesis.19,20 Consistent with this, mice with a tar-
geted inactivation of scleraxis fail to properly form
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limb tendons during embryonic development.21
TGF-b appears to play an important role in scler-
axis expression during development, as TGFbRII
knockout (KO) embryos have a marked reduction
in scleraxis expression and a subsequent disruption
in the formation of limb tendons.22 Although TGF-
b appears to be important in the induction of scler-
axis expression during development, the role that
TGF-b plays in regulating scleraxis expression in
ﬁbroblasts of adult skeletal muscle is not known.
To gain a greater understanding of the role of
TGF-b in the regulation of skeletal muscle atrophy
and ﬁbrosis, we determined the impact of recombi-
nant TGF-b treatment on the contractile and mor-
phological properties of skeletal muscles from the
anterior compartment of the lower hindlimb of
transgenic mice that express green ﬂuorescent pro-
tein (GFP) under the control of 4 kb of the scler-
axis promoter. We also determined the effect of
TGF-b treatment on the levels of atrogin-1, scleraxis,
and procollagen I protein content in muscles. We
hypothesized that, compared with control muscles,
muscles treated with TGF-b would have a reduction
in maximum isometric force, an induction of mus-
cle ﬁber atrophy, and an increase in atrogin-1, scler-
axis, and procollagen Ia2 protein levels.
METHODS
Animals. All experiments were conducted with ap-
proval from the committee on the care and use of
animals at the University of Michigan. Four-month-
old male mice that express GFP under the control
of 4 kb of the scleraxis promoter (ScxGFP mice)
were used in this study.18 The ScxGFP strain of mice
was kindly provided by Dr. Ronen Schweitzer. Mice
were housed under speciﬁc pathogen-free condi-
tions and provided food and water ad libidum.
TGF-b Treatment and Operative Procedure. Mice
were anesthetized with isoﬂurane, and the hin-
dlimbs were shaved and cleaned. For each mouse,
100 ll of a solution containing 2 ng/ml of
recombinant TGF-b (R&D Systems) in sterile phos-
phate-buffered saline (PBS; Thermo Scientiﬁc) was
carefully injected subcutaneously around the ante-
rior compartment of the left lower hindlimb, and
100 ll of sterile PBS (vehicle only) was injected
subcutaneously around the anterior compartment
of the right lower hindlimb. Mice were allowed to
recover and were returned to their cages. Five days
after injections, the extensor digitorum longus
(EDL) and tibialis anterior (TA) muscles were
removed under isoﬂurane anesthesia, and the mice
were humanely euthanized. The EDL muscle was
used for contractility and histology experiments,
whereas the TA muscle was used for immunoblots.
Skeletal Muscle Contractility. The contractility of
EDL muscles was measured in vitro as previously
described.23 Brieﬂy, EDL muscles were placed in
Krebs mammalian Ringer solution supplemented
with 0.25 mM tubocurarine chloride, the proximal
tendon was attached to a force transducer
(Kulite Semiconductor), and the distal tendon was
attached to a servomotor (Aurora Scientiﬁc). The
solution was maintained at 25C and was bubbled
with 95% O2 and 5% CO2 to stabilize the pH at
7.4. An IBM PC running custom-designed Lab-
VIEW software (National Instruments) was used to
control experiments and store data. EDL muscles
were stimulated by square wave pulses delivered
from two platinum electrodes connected to a high-
power biphasic current stimulator (Aurora Scien-
tiﬁc). The voltage of pulses was increased, and
muscle length was adjusted to the length (Lo) that
resulted in maximum twitch force (Pt). The time
to peak tension (TTPT) of twitches and half-relaxa-
tion time (HRT) for twitches were also recorded.
After twitch force measurement, muscles were
maintained at Lo and subjected to 300-ms pulse
trains to generate an isometric contraction. Stimu-
lus frequency was increased until maximum iso-
metric force (Po) was achieved, typically around
120 HZ. The maximum rate of force development
during the development of an isometric contrac-
tion (maximum dP/dt) was also determined. After
contractile properties were determined, muscles
were subsequently removed from the bath, mass
was measured, and muscles were quickly frozen in
TissueTek (Triangle Biomedical Sciences) for his-
tological assessment. To determine speciﬁc Po
(sPo), it was normalized by cross-sectional area
(CSA), measured histologically. This approach was
chosen instead of normalizing by physiological
CSA (PSCA), because the amount of ﬁbrosis in the
TGF-b–treated muscles likely increased the density
of muscles beyond the standard density of healthy
skeletal muscle, 1.056 g  cm3.24
Histology. Muscles were sectioned at the midbelly
with a cryostat at a thickness of 10 lm. Sections
were permeabilized using a 0.2% Triton X-100 so-
lution and blocked using a blocking kit (Mouse on
Mouse; Vector Labs). Satellite cells were identiﬁed
using a primary antibody against c-met (Santa
Cruz) and an AlexaFluor 546–conjugated second-
ary antibody (Invitrogen). A biotinylated primary
antibody against collagen I (AbCam) and Alexa-
Fluor 647 conjugated to streptavidin (Invitrogen)
was used to identify extracellular matrix. Nuclei
were identiﬁed using DAPI. Slides were mounted
in Prolong Gold (Invitrogen) and imaged using an
Axioplan 2 microscope (Zeiss). Histomorphometry
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of digital images was performed using ImageJ
software.
Immunoblots. TA muscles were homogenized in
Laemmli sample buffer with 1:20 b-mercaptoetha-
nol and 1:20 protease inhibitor cocktail (Sigma)
and then placed in boiling water for 2 minutes.
Protein concentration was determined using a
non-interfering protein assay (G-Biosciences), and
15 lg of protein was loaded into AnyKD mini-gels
(BioRad) and subjected to electrophoretic separa-
tion. For atrogin-1, scleraxis, and b-tubulin blots,
proteins were transferred from gels onto polyvinyli-
dene ﬂuoride (PVDF) membranes (Millipore),
blocked with 2% goat serum, and incubated with
antibodies against atrogin-1 (ECM Biosciences),
scleraxis (AbCam), or b-tubulin (AbCam). Procol-
lagen I blotting was performed by transferring pro-
teins from gels onto nitrocellulose membranes
(Bio-Rad), which were subsequently placed in 95C
water for 5 minutes, blocked with 5% non-fat pow-
dered milk, and incubated with antibodies against
procollagen I (Santa Cruz). After primary antibody
incubation, membranes were rinsed and incubated
with horseradish peroxidase–conjugated secondary
antibodies (Santa Cruz). Proteins were detected
using enhanced chemiluminescent reagents
(SuperSignal West Dura; Pierce) and visualized
using a digital chemiluminescent documentation
system (Alpha Innotech).
Statistical Analyses. Results are presented as mean
6 SE. KaleidaGraph 4.1 software (Synergy) was
used to conduct statistical analyses. Differences
between groups were tested using the Student
t-test with a ¼ 0.05.
RESULTS
The morphological and contractile properties of
EDL muscles treated with vehicle (TGF-b) or
with 200 pg of recombinant TGF-b (þTGF-b) are
shown in Table 1. The treatment of muscles with
TGF-b did not change muscle mass, but did result
in a 21% decrease in the CSA of whole EDL
muscles and a 38% reduction in the CSA of indi-
vidual EDL muscle ﬁbers (Table 1). Consistent
with an induction of muscle atrophy and accumu-
lation of ECM, the contractile forces of TGF-b–
treated muscles were also reduced. Compared with
control muscles, TGF-b–treated muscles had a 75%
reduction in Pt, a 66% reduction in sPt, no change
in TTPT, and an 89% increase in HRT (Table 1).
For isometric contractions, TGF-b–treated muscle
displayed a a 72% decrease in Po, a 61% reduction
in sPo, and a 73% reduction in maximum dP/dt
(Table 1).
In control muscles from ScxGFP mice, scleraxis
was expressed in ﬁbroblasts in the perimysium as
well as in the epimysium, and these scleraxis-
expressing ﬁbroblasts were often located adjacent
to satellite cells (Fig. 1A). TGF-b treatment
resulted in the activation of these ﬁbroblasts, an
increase in the collagen I content of the muscle
ECM, and atrophy of muscle ﬁbers (Fig. 1B). Com-
pared with vehicle-treated muscles, treatment with
TGF-b also increased the levels of scleraxis, procol-
lagen Ia2, and atrogin-1 levels in muscles as meas-
ured by immunoblot (Fig. 2). b-tubulin is used as a
loading control to verify equal protein loading
(Fig. 2).
DISCUSSION
The signiﬁcance of this study lies in the new
insights gained into the role of TGF-b in the
induction of skeletal muscle atrophy and ﬁbrosis.
Table 1. Morphological and contractile properties from vehicle-
treated (–TGF-b) and TGF-b–treated (þTGF-b) EDL muscles.
–TGF-b þTGF-b
Mass (mg) 10.0 6 0.3 9.8 6 0.6
Whole-muscle CSA (mm2) 1.74 6 0.14 1.38 6 0.13*
Muscle fiber CSA (lm2) 1156.9 6 76.2 716.5 6 42.5*
Twitch
Pt (mN) 119.4 6 5.4 29.3 6 8.8*
sPt (mN/mm
2) 71.5 6 6.5 24.0 6 7.2*
TTPT (ms) 17.3 6 1.9 17.4 6 1.6
HRT (ms) 16.3 6 0.4 30.9 6 2.8*
Isometric
Po (mN) 387.6 6 4.2 110.0 6 32.2*
sPo (mN/mm
2) 231.8 6 19.6 89.3 6 26.6*
Maximum dP/dt (mN/ms) 14.1 6 0.6 3.8 6 1.2*
Data expressed as mean 6 SE (N ¼ 7). See text for abbreviations.
*Significant difference vs. –TGF-b (P < 0.05).
FIGURE 1. Immunohistochemistry of EDL muscles treated with
PBS (A) or TGF-b (B). Nuclei (DAPI): blue; Collagen I: red; sat-
ellite cells (c-met): orange; fibroblasts (ScxGFP): green. Scale
bar ¼ 5 lm. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
FIGURE 2. Immunoblot of atrogin-1, scleraxis, procollagen Ia2,
and b-tubulin from TA muscles of paired hindlimbs from 4 repre-
sentative mice treated either with PBS (TGF-b) or with TGF-b
(þTGF-b). b-tubulin is used as a loading control.
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In addition, by measuring the contractile proper-
ties of muscles, we demonstrated for the ﬁrst
time that TGF-b causes a dramatic reduction in
the force-generating capacity of otherwise healthy
muscle tissue. Previous studies of the effects of
TGF-b in skeletal muscle have utilized direct in-
jurious intramuscular injections of TGF-b or have
correlated TGF-b levels with the severity of mus-
cle disease or injury pathology. Our approach
allowed us to speciﬁcally evaluate the effect of
TGF-b in intact whole muscle tissue without the
confounding effects of direct muscle injury or
disease.
Our results indicate that TGF-b can directly
induce muscle ﬁber atrophy in the absence of
physical injury to muscle and in a satellite cell–
independent fashion. We observed a decrease in
muscle ﬁber CSA in TGF-b–treated muscles and,
although no change in whole muscle mass was
observed, any reduction in muscle mass due to
individual ﬁber atrophy was likely offset by the
accumulation of collagen in the muscle ECM.
TGF-b plays an important role in the regulation of
skeletal muscle satellite cell activity. TGF-b can
cause satellite cell apoptosis and can potently in-
hibit the proliferation and fusion of satellite cells,
even in the presence of the mitogenic growth
factors IGF-1 and ﬁbroblast growth factor-2
(FGF-2).25–28 A cytokine related to TGF-b, myosta-
tin, activates similar signaling pathways as TGF-b
and also inhibits satellite cell proliferation and
fusion.29,30 As satellite cells play an important role
in the regeneration of muscle ﬁbers after injury,31
an inhibition of satellite cell activity during muscle
regeneration could lead to muscle ﬁber atrophy.
Our observations of individual ﬁber atrophy in
muscles exposed to TGF-b in the absence of muscle
injury support effects of TGF-b that are independ-
ent of its known effects on satellite cells.
The association demonstrated in this study of
TGF-b–induced ﬁber atrophy with an upregulation
of expression of the E3 ubiquitin ligase atrogin-1 is
consistent with ﬁndings by Sartori and col-
leagues,32 who demonstrated that transfection of a
constitutively active TGFbRI into the tibialis ante-
rior muscles of mice resulted in muscle ﬁber atro-
phy and a Smad3-dependent activation of the atro-
gin-1 promoter. In addition, in the model system
Caenorhabditis elegans, expression of MFB-1, an atro-
gin-1 homolog, is regulated by the TGF-b homo-
log, DAF-7.33 Although the regulation of satellite
cell activity is an important factor in determining
muscle ﬁber size, taken together these results sug-
gest that TGF-b may directly induce muscle ﬁber
atrophy, at least in part, by increasing the atrogin-1
protein levels within muscle ﬁbers. Further studies
that evaluate speciﬁc components of the TGF-b
signal transduction pathway will provide additional
insight into the molecular mechanisms of TGF-b–
mediated skeletal muscle atrophy.
Although much attention has focused on the
role of satellite cells in the determination of mus-
cle function, relatively little attention has been
paid to the biology of muscle ﬁbroblast cells. Li
and colleagues4 undertook direct intramuscular
injection of 5 ng of recombinant TGF-b into the
TA muscles of mice and observed a dramatic
induction of ﬁbrosis and muscle ﬁber atrophy.
Using less than one twentieth of this dose deliv-
ered subcutaneously, we also observed a decrease
in the size of muscle ﬁbers and an increase in col-
lagen I levels in muscle. Li et al.4 also reported
that, when C2C12 myoblast cells that were modiﬁed
to overexpress TGF-b were injected into immuno-
deﬁcient mice, these transplanted myoblast cells
displayed the ability to transdifferentiate into ﬁbro-
blasts in vivo. In control muscles, we identiﬁed a
population of ﬁbroblast cells that express scleraxis.
Interestingly, in many cases, these ﬁbroblasts were
located adjacent to quiescent satellite cells. In
response to TGF-b treatment, the number of ﬁbro-
blasts did not appear to change; instead, the cells
became enlarged, had an increase in scleraxis lev-
els, and showed greater accumulation of collagen I
in their surrounding ECM. These results support
the notion that TGF-b signaling regulates the activ-
ity of ﬁbroblast cells in skeletal muscle and that
scleraxis may be an important regulator of ﬁbrosis
in adult skeletal muscle tissue.
After injury to skeletal muscle, there is an
increase in the expression of TGF-b34,35 and an
activation of the TGF-b molecules that are present
in the ECM around muscle ﬁbers,36 although the
role of TGF-b in the injury and recovery process is
not clear. TGF-b also appears to play an important
role in muscle wasting associated with congenital
diseases such as Duchenne muscular dystrophy.8
Suramin, a polysulfonated naphthylurea molecule,
was found to improve the regeneration of skeletal
muscles in mdx mice37 and also improved the re-
covery of muscles after injury.38–40 Suramin inhibits
the binding of several growth factors to their
receptors, including the proinﬂammatory cytokines
TGF-b and myostatin, and the anti-inﬂammatory
and protein synthesis cytokines FGF-1, FGF-2, IGF-
1, and platelet-derived growth factor (PDGF).40,41
Although the non-speciﬁc inhibition of TGF-b
using a compound like suramin offers some prom-
ise, the use of a more speciﬁc inhibitor of TGF-b
may further promote muscle regeneration by
blocking the cachectic effects of TGF-b signaling
without reducing the activities of other anabolic
growth factors. Identifying other cytokines that
control the expression of atrogin-1 and scleraxis
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may also promote functional muscle regeneration
and reduce the deposition of scar tissue.
The ScxGFP mice were a kind gift provided by Dr. Ronen Schweit-
zer. This work was supported by grants AR058920 and AR055624
fromNational Institute of Arthritis and Skin Diseases.
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